Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.44 |
| ▸ | NOS3 | P29474 | 9/20 | 0.44 |
| ▸ | NOS1 | P29475 | 8/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229274 | 0.87 | NOS2 (0.46) | NOS2NOS3NOS1KLKB1 | |
| SCHEMBL19067633 | 0.83 | IKBKB (0.34) | NOS2NOS3NOS1KDM4E | |
| SCHEMBL18310670 | 0.80 | NOS2 (0.43) | NOS2NOS3NOS1 | |
| SCHEMBL17229289 | 0.78 | NOS2 (0.50) | NOS2NOS3NOS1KLKB1 | |
| SCHEMBL18314725 | 0.75 | NOS2 (0.48) | NOS2NOS3NOS1 | |
| SCHEMBL17229305 | 0.75 | NOS2 (0.47) | NOS2NOS3NOS1KLKB1KDM4E | |
| SCHEMBL17229310 | 0.73 | NOS2 (0.42) | NOS2NOS3NOS1KLKB1KDM4E | |
| SCHEMBL17229350 | 0.72 | NOS2 (0.45) | NOS2NOS3NOS1KLKB1 | |
| SCHEMBL9607432 | 0.70 | TLR8 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL18310645 | 0.70 | NOS2 (0.43) | NOS2NOS3NOS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | NOS2 4129/4885NOS3 3599/4885NOS1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.